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ABSTRACT
Objective: We aimed to investigate the metabolic characteristics of Solid 
pseudopapillary neoplasms (SPNs) in relation signal intensities on 18F-FDG PET scans.
Summary Background Data: SPNs of the pancreas commonly show high uptake of 
18F-FDG. However, the metabolic characteristics underlying the high 18F-FDG uptake 
in SPNs are not well characterized.
Materials and Methods: mRNA expressions for glucose metabolism were 
analyzed in five SPNs, five pancreatic ductal adenocarcinomas (PCAs), and paired 
normal pancreatic tissues. Among the proteins involved in glucose metabolism, the 
expressions of five proteins (GLUT1, HK1, PFKM, ENO2, and PKM2) were evaluated 
in 36 SPNs by immunohistochemistry. Clinical patterns of SPN on PET scans were 
classified according to the proportion of 18F-FDG uptake within the whole tumor 
volume (hot: ≥ 70%, mixed: 30 ≤ < 70, and defective: < 30%). PET-based parameters, 
including maximum standardized uptake value (SUVmax) and metabolic tumor volume 
(TMV2.5), were evaluated.
Results: Hot (n = 19), mixed (n = 5), and defective (n = 12) 18F-FDG uptake 
patterns were noted in the 36 patients. Radiologic tumor size and SUVmax differed 
significantly according to these patterns (ANOVA, p < 0.05). GLUT1, HK1, PFKM, 
ENO2, and PKM2 were highly expressed in SPNs at both the mRNA and protein levels. 
Defective type SPNs showed lower expression of HK1 (p = 0.014), PKM2 (p = 0.028), 
and Ki-67 (p = 0.070) with frequent intra-tumoral necrosis (p = 0.007). High Ki-67 
expression (≥ 3%) was associated with high SUVmax in pancreatic SPNs (p = 0.002).
Conclusions: SPN cells harbor an active molecular capacity for increased glucose 
metabolism. Especially, defective type SPNs were associated with low metabolic 
activity and related to low Ki-67 index.
INTRODUCTION
Solid pseudopapillary neoplasm (SPN) is a very rare 
pathologic condition of the pancreas. It accounts for only 
1–3% of all exocrine pancreatic tumors and 6–12% of all 
cystic tumors of the pancreas. In spite of its clinical rarity, 
clinical reports related with differential diagnosis have 
increased. In fact, a recent Korean nationwide survey of 
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cystic neoplasms of the exocrine pancreas [1] found SPNs 
to rank as the third most common cystic neoplasm of the 
pancreas (18.3%, 195 out of 1064 patients), indicating 
that pancreatic SPNs may not be uncommon in Korea. 
Reportedly, approximately 10 to 15% of cases of SPN are 
malignant, although complete surgical resection of these 
tumors can promise long-term survival, even in cases of 
distant metastasis and peritoneal seeding [2–5]. Although 
additional genetic analysis is required to identify the 
exact mechanism for tumorigenesis of SPN, studies have 
recently found that SPNs exhibit β-catenin gene mutation 
[6, 7]. Diffuse cytoplasmic and nuclear localization of 
β-catenin is indeed found in SPN. β-catenin functions 
as a downstream transcriptional co-activator of the Wnt 
signaling pathway; therefore, the Wnt signal pathway is 
thought to play an important role in the tumorigenesis of 
SPN. 
According to clinical experience and reports in the 
literature, [8–11]. SPNs commonly exhibit high uptake of 
18F-FDG. However, investigations into the mechanisms for 
18F-FDG uptake in SPNs are scarce. In 2006, Sato, et al. 
[12] reported poor expression of GLUT1 and moderate 
expression of HK2 on immunohistochemistry staining in 
SPN cells, suggesting that FDG accumulation might be 
related to tumor cell density and rich mitochondria, based 
on the analysis of two cases. Notwithstanding, 18F-FDG 
PET scan can reveal the metabolic and biologic activity of 
tumors, and it only focuses on the initial steps of glucose 
metabolism, such as glucose transport and hexokinase 
activity, not the entire pathway of glucose metabolism. 
Therefore, in this study, we investigated the metabolic 
characteristics of SPNs of the pancreas in relation signal 
intensities on 18F-FDG PET scans.
RESULTS
Clinical patterns of 18F-FDG uptake in SPNs
36 patients with SPNs underwent an 18FDG-PET 
scan during preoperative evaluation. 35 patients (97.2%) 
were female and only one was male, with an overall mean 
age of 34.8 ± 11.2 years. Radiologic tumor size was 4.8 
± 2.8 cm in maximum diameter. PET-related parameters 
were calculated in all SPNs. SUVmax was 5.5 ± 4.1 (g/
cm3), and MTV2.5 was 31.5 ± 59.6 (cm
3). A hot uptake 
pattern was identified in 19 patients (Figure 1A, and 1B, 
52.8%), mixed pattern in five (Figure 1C, and 1D, 13.8%), 
and defective pattern in 12 patients (Figure 1E, and 1F, 
33.4%). 
When analyzing clinical patterns of 18FDG-uptake 
with radiologic tumor size and PET-parameters, radiologic 
tumor size (p = 0.002) and SUVmax (p = 0,001) differed 
significantly according to pattern of 18F-FDG uptake in 
SPNs. Mixed type SPNs were larger in size and showed 
higher intensities of 18FDG uptake (ANOVA, p < 0.05, 
Figure 1G, 1F and Supplementary Table 1). 
Gene expression profiles for glucose metabolism 
in SPNs
We analyzed and compared the expression of genes 
involved in glucose metabolism and β-catenin in SPNs, 
normal pancreas and PCA specimens. These data were 
selectively obtained from our previous microarray study 
[13]. Typically, greater over-expression of β-catenin was 
noted in SPNs, compared with PCA (4.3-fold in SPN 
compared to normal pancreatic tissue, p = 0.003, and 
1.6-fold in PCA, p > 0.05; Figure 2A and Supplementary 
Table 2). Expression of GLUT1 was significantly higher 
in PCAs than SPNs (2.2-fold in SPN, p < 0.05, 11.0-fold 
in PCA, p < 0.01). However, GLUT12 was significantly 
higher in SPNs than PCA (in SPN, 19.8-fold, p < 0.001 
and in PCAs, 2.1-fold, p = 0.067). GLUT14 was highly 
expressed in both SPNs and PCAs of the pancreas, 
compared with normal pancreatic tissue (0.001< p < 0.05). 
Glucose transporter, GLUT6, was expressed in both SPNs 
and PCAs, compared to normal pancreatic tissue, with 
significance (0.01< p < 0.05) (Supplementary Table 2). 
Hexokinases were also highly expressed in both SPNs 
and PCAs, although HK1 was strongly over-expressed in 
SPNs, compared with PCAs (7.0-fold in SPN, p < 0.01 
and 3.7-fold in PCA, p < 0.01). Meanwhile, expression 
of HK2 in SPNs was similar to that in normal pancreatic 
tissue (1.9-fold, p > 0.05), and higher in PCAs (4.8-fold, p 
< 0.01). In addition, PFKM (phosphofructokinase, muscle), 
ENO2 (enolase-2), and PKM2 (pyruvate kinase) were also 
significantly overexpressed in SPNs. Together, these data 
suggest that SPNs have a sufficient molecular apparatus 
from which to active glucose metabolism (Supplementary 
Table 2 and Supplementary Figure 2).
Interestingly, expression of PDHB (pyruvate 
dehydrogenase) was similar in SPNs (1.0-fold, p > 0.1) and 
PCAs (-1.1-fold, p > 0.1), compared to normal pancreatic 
tissue. Meanwhile, LDHA (lactate dehydrogenase) was 
significantly overexpressed in PCAs, compared with 
normal pancreatic tissue (, 2.9-fold, p < 0.01), in contrast 
to SPNs in which expression of LDHA was lower than that 
in normal pancreatic tissue, but there were no statistical 
difference. (-1.1-fold, p > 0.1) (Supplementary Table  2 
and Supplementary Figure 2).
Protein expression for glucose metabolism in 
SPNs
 We performed western blot analysis for the 
expressions of GLUT1, HK1, PFKM, ENO2, and PKM2 
in the same specimens used in the microarray analysis. 
As shown in gene expression data, overexpression of 
HK1, ENO2, and PKM2 were also noted at the protein 
level (Figure 2B). Expression of HK1 and ENO2 were 
apparently unique to SPNs, compared to PCAs. Greater 
expression of the GLUT1 gene in SPNs was noted (2.2-
fold, p = 0.012), compared with PCA (11-fold, p < 0.001, 
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Figure 2A and Supplementary Table 2); however, GLUT1 
expression at the protein level was similar between SPNs 
and PCAs. The expressions of PDHB and LDHA in SPNs 
were similar to those in normal pancreatic tissue, although 
expression of LDHA was greater in PCAs, as observed in 
the gene expression data.
Immunohistochemistry for glucose metabolism 
in SPNs
Most of the glucose metabolism-related genes 
found in the DNA microarray analysis were confirmed 
in immunohistochemical analysis of resected SPNs 
(Supplementary Figure 1 and Table 1). GLUT1 was found 
to be expressed in 31 patients (86.1%, Supplementary 
Figure 1A). Greater expression of ENO2 was also noted 
compared with normal acinar cells (Supplementary Figure 
1C). LDHA and PDHB expression was also observed in 
all patients, which seemed similar to or less than that 
in normal acinar cells (Supplementary Figure 1E, and 
1F). However, HK1 was significantly expressed in the 
26 patients (Supplementary Figure 1B), and PKM2 was 
clearly expressed in 20 patients (76.9%, Supplementary 
Figure 1D). All SPNs showed very low proliferative 
index in Ki-67 (Supplementary Figure 1G, and 1H). Ki-
67 expression less than 3% (range, 0–5%) was found in 
almost all patients (94.4%), and 23 SPNs (63.8%) showed 
Ki-67 expression less than 1%. Immunohistochemistry 
for identifying glucose metabolism-related genes was also 
performed in 5 patients with PCAs (Supplementary Table 
3). As expected, GLUT1 was expressed in all 5 patients; 
however, HK1 was rarely expressed and no ENO2 
expression was noted in PCAs. Compared to SPNs, PKM2 
and LDHA were more strongly expressed in PCAs.
Figure 1: Clinical patterns of 18FDG-uptake in SPN of the pancreas. Clinical patterns of 18F-FDG uptake in SPNs were 
categorized according to the proportion of 18F-FDG uptake over the whole tumor volume (Hot type: ≥ 70% (A, B), Mixed type: 30% ≤ < 
70% (C, D), and Defective type: < 30% (E, F)). When correlating the clinical patterns of 18FDG-uptake with radiologic tumor size and 
PET-parameters, radiologic tumor size (G, p = 0.002) and SUVmax (H, p = 0,001) were significant different according to pattern of 18F-FDG 
uptake in SPNs of the pancreas. Mixed type of SPN was shown to be large in size with high intensity of 18FDG uptake. (**ANOVA, p > 0.05).
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Correlation between PET-based parameters and 
glucose metabolism-related gene expressions in 
SPN
 GLUT1 expression was not associated with 
18FDG-uptake intensity in SPNs. There was no 
difference in GLUT1 expression according to pattern 
of 18FDG-uptake (p = 0.646, Supplementary  Table 4). 
However, expression of HK1 (p = 0.014) and PKM2 
(p = 0.028) were found differ according to pattern of 
18FDG-uptake. Expression of HK1 and PKM2 decreased 
in defective pattern, comparing with hot and mixed 
patterns (Supplementary Figure 3A, and 3B). Intra-
tumoral necrosis was significantly associated with 
defective type SPNs (p = 0.007, Supplementary Figure 
3C, and Supplementary Table 4). In addition, there 
was a significant association between intra-tumoral 
necrosis and Ki-67 index (p = 0.017, Table 2), indirectly 
suggesting SPNs with intra-tumoral necrosis are related 
with a lower Ki-67 index. Therefore, defective type had 
a tendency to show lower proliferation power, compared 
with hot and mixed SPNs (p = 0.07, Supplementary 
Figure 3D). Also, SPNs with high 18F-FDG intensity 
(SUVmax) showed higher Ki-67 index (ANOVA, p = 
0.002, Figure 3). 
Correlation between expression of glucose 
metabolism-related genes, patterns of FDG 
uptake, and microscopic malignant feature of 
SPNs
Seven (19.4%) out of 36 patients were found to 
have microscopic malignant features in resected SPNs. 
Microscopic malignant features included capsule invasion, 
perineural invasion, vascular invasion, infiltrative to 
pancreatic tissue, and peripancreatic tissue invasion. PET-
based parameters (SUVmax and MTV2.5) were similar between 
SPN groups with microscopic benign and microscopic 
malignant features (p > 0.05, Table 3). There were no 
relationships between expression of GLUT1, HK1, and 
PKM2, as well as Ki-67 index, and microscopic malignant 
features (p > 0.05). However, defective type SPNs tended to 
be associated with benign-looking SPNs, compared with hot 
and mixed type SPNs, although this difference did not reach 
statistical significance (p = 0.070, Table 4).
DISCUSSION
To date, SPN characteristics on 18F-FDG PET or PET/
CT have rarely been reported. According to the literature, the 
intensity of 18FDG-uptake in SPNs varies widely. In some 
Figure 2: mRNA expression profiles and protein levels of genes for glucose metabolism in SPN. Gene expression profiles 
of SPNs showed increased expression of genes involved in glucose metabolism. Note that LDHA is highly expressed in PCA comparing to 
normal pancreatic tissue, but it slightly decreased in SPN without statistical significance (A) See also Supplementary 2). Protein levels of 
HK1, ENO2, and PKM2 were overexpressed. Expression of HK1 and ENO2 were upregulated specifically in SPNs, compared to PCAs. 
Meanwhile, protein expression of GLUT1 was similar between SPNs and PCAs. The expressions of PDHB and LDHA in SPNs were 
similar to those in normal pancreatic tissue, although expression of LDHA was greater in PCAs (B). SPN, solid pseudopapillary tumor; 
PCA, pancreatic ductal adenocarcinoma.
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reports, [14, 15] SPNs with mild or no 18F-FDG uptake have 
been presented, while others have described SPNs with 
intense 18F-FGD uptake [8, 9, 12, 16, 17]. With accumulating 
clinical experience in SPN, application of PET scans to 
SPNs of the pancreas has expanded to testing its capacity 
to differentiate SPNs from other malignant tumors, such as 
pancreatic cancer or neuroendocrine tumor, [10, 11, 18, 19] 
in addition to its clinical usefulness in staging and treatment 
planning [16, 17]. Although several reports of high 18F-FDG 
uptake in SPN have been published, research on the metabolic 
mechanisms of SPNs is rarely reported. It is thought that any 
tumor will cause the alterations of the glucose metabolism, 
then glucose metabolism should not be the specific for 
SPNs. However, there was no study to investigate glucose 
metabolic alteration in SPNs to confirm this assumption. The 
exact mechanisms involved in glucose uptake by SPNs are 
still unknown. Therefore, we primarily tried to overview the 
landscape of altered glucose metabolism in resected SPNs of 
the pancreas, especially comparing with pancreatic cancer.
In present study, based on our previous research of 
characterizing gene expression profiles for SPNs, [13]. we 
investigated the molecular mechanisms of 18F-FDG uptake 
in SPNs. To the best of our knowledge, the present study 
is the first to report on a molecular mechanism of glucose 
metabolism in SPNs. According to our data, SPNs show 
a distinct molecular apparatus for glucose uptake and 
for glycolysis to form pyruvate. We found that GLUT1, 
GLUT6, GLUT12, and GLUT14 are highly expressed in 
SPNs. GLUT1, known as a principal glucose transporter 
in tumors, was expressed even at the protein level. In 
addition, enzymes involved in glycolysis, such as HK1, 
ENO2, and PKM2, were also overexpressed, and this was 
confirmed in both western blot and immunohistochemistry 
experiments. These molecular profiles strongly suggest 
that neoplastic cells of SPN possess an increased capacity 
for glucose metabolism, which is observable in the 
appearance of SPNs on 18F-FDG -PET scans.
This study also attempted to categorize clinical 
patterns of 18F-FDG uptake in SPNs. We previously 
classified patterns of 18F-FDG uptake in SPNs into five 
categories [20]. In addition, we also tried to categorize 
SPNs according to different 18F-FDG-uptake proportion 
such as, < 10%, 10%–30%, 30–50%, 50–70%. 70–
90%, and 90% <, and the similar relationship with the 
present results were founded (data not shown). These 
classification system looks very specific, but it was found 
that these categories were complex and confused to apply 
in clinical practice. So, we slightly modified previous five 
categories simply into Hot uptake (previously belong to 
type I and type II), Mixed (previously belong to type III), 
and Defective type (previously belong to type IV and V) 
in this study based on the proportions of 18F-FDG uptake 
within the whole tumor.
In the present study, we found that intra-tumoral 
necrosis was found to be associated with low Ki-67 
index (Table 2), and defective type SPNs were related 
to intra-tumoral necrosis and a lower Ki-67 index 
(Supplementary Figure 3C, and 3D). These observations 
indirectly suggest that defective type SPNs may be less 
likely to progress. Defective type SPNs, resulting from 
Figure 3: SUVmax values according to Ki-67 Index. SPNs with high 18F-FDG intensity (SUVmax) showed higher Ki-67 index 
(ANOVA). *p = 0.002, a number beside the box shows the mean value of SUVmax 
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intra-tumoral hemorrhagic necrosis due to weakened 
cell-to-cell adhesion, [21] can cause chronic hypoxia 
and ischemic necrosis of viable solid portions of the 
tumor. If the tumors are not clinically detected, even 
at this stage, and/or not treated immediately, a totally 
necrotic tumor of the pancreas might be found. Recently, 
we proposed that marginally calcified, totally necrotic 
pancreatic tumors might comprise a subset of SPNs 
with near total necrosis [22] (perhaps defective type 
SPN), and the present observation may support this 
hypothesis. It is also interesting to note that the clinical 
patterns of 18F-FDG uptake in SPNs apparently represent 
the metabolic activity of SPN. Expression of HK1 and 
PKM2 were closely correlated with patterns of 18F-FDG 
uptake (Supplementary Figure 3A, 3B and Supplementary 
Table 4). More frequent expression of HK1 and PKM2 
were noted in hot and mixed pattern, compared to the 
defective pattern. Pyruvate kinase is the last rate-limiting 
enzyme in glycolysis, and catalyzes the conversion of 
phosphoenolpyruvate and ADP into pyruvate and ATP. 
PKM2 is known to be expressed predominantly in tumor 
cells, and is important for cancer metabolism and tumor 
growth. A previous study showed that PKM2 expression 
is involved in early tumorigenesis [23]. and that increases 
in PKM2 levels are correlated with tumor size and stage 
[24]. HK catalyzes the conversion of glucose to glucose-6-
phosphate, the first and rate-limiting step in the glycolytic 
pathway. Usually, HK2 is regarded as a principle enzyme 
in cancer metabolism; however, our study suggests that 
HK1 is the main enzyme converting glucose to glucose-
6-phosphate in SPNs. Nevertheless, the exact role of HK1 
and PKM2 in the tumorigenesis of SPN remains to be 
investigated further (Supplementary Figure 2). 
We also found that SPNs with high Ki-67 index are 
related with high SUVmax (Figure 7). Tumor size and PET-
related parameters, such as SUVmax, were larger and higher 
in mixed type SPNs (Figure 2 and Supplementary Table 1), 
suggesting mixed type SPNs may be a biologically active 
tumor with higher Ki-67 index. Due to the limited number 
of mixed type SPNs in our data set (n = 5 patients), it 
would have been difficult for us to definitively examine this 
potential relationship; however, this observation is thought 
to be very important, because Ki-67 index and tumor 
proliferation have been previously reported to associated 
with aggressive biological behavior of SPNs [25–27]. 
Recently, Yu, et al. [28] also demonstrated that positive 
immunoreactivity for Ki-67 may predict the malignant 
potential and poor outcomes of SPN. Nakagohri, et al. [14] 
reported that most SPNs (5 out of 6 tumors) show strong 
accumulation of FDG on PET scans, and showed that 
SPNs with high FDG uptake were related to microscopic 
venous and perineural invasion. Conversely, the tumors 
without intense FDG uptake had neither microscopic 
venous invasion nor nerve invasion, suggesting a potential 
relationship between SUV and histological malignancy. In 
our data, we observed no relationship between malignant 
microscopic features in resected SPNs and GLUT1, HK1, 
intratumoral necrosis, and Ki-67 index. However, patterns 
of 18F-FDG uptake in SPNs were found to be related to 
microscopic malignant features of SPN with marginal 
significance (p = 0.070, Table 4). 
Therefore, clinically, it can be recommended 
that SPT with high SUVmax (for example, hot uptake 
and mixed type) should be aggressively treated from 
the metabolomics point of view, because PET-based 
parameter, especially high SUVmax was related to 
Figure 4: Proposing surgical strategy for SPTs of the pancreas based on the pattern of 18F-FDG uptake. Surgical decision-
making can be specified according to clinical pattern of 18F-FDG uptake in patients with SPN. 
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increased Ki-67 index. In addition, small hot-uptake 
type of SPT should be considered for resection because 
it is difficult to differentiate from other malignant 
tumors of the pancreas, such as pancreatic cancer, 
and neuroendocrine tumor, when the tumor did not 
show typical radiologic characteristics of SPNs of the 
pancreas [11, 18]. On the other hand, defective type 
of SPNs was associated with low expression of HK1/
PKM2, intratumoral necrosis, and tended to have lower 
proliferation with low metabolic capacity (Figure 1H, 
Table 1: Immunohistochemical results of glucose metabolism-related genes in SPN
Case# Gender Age Tumor Size (cm)
18FDG-
uptake 
pattern
GLUT1 HK1 ENO2 PKM2 Ki-67 Necrosis
1 Female 25 5.6 Hot + + + +/- < 1% -
2 Female 46 5 Defective - ++ + + < 1% -
3 Female 38 3.5 Mixed + ++ + N/A < 1% +
4 Female 28 5 Defective + N/A + N/A < 1% +
5 Female 28 6.8 Hot + N/A + N/A < 1% +
6 Female 24 8.2 Hot + ++ + + < 1% -
7 Female 32 1.7 Hot + ++ + + 1-2% -
8 Female 25 4.9 Defective + ++ + + 1–2% -
9 Female 31 5.3 Defective + N/A + N/A 0% +
10 Female 46 6.5 Defective + N/A + N/A 0% +
11 Female 45 2.3 Mixed + ++ + + < 1% -
12 Female 12 10.1 Mixed + ++ + + 3% ≤ -
13 Female 25 12.3 Hot + N/A + N/A 1–2% +
14 Female 35 1.3 Hot + ++ + + 1–2% -
15 Female 24 5.7 Hot + ++ + + < 1% -
16 Female 62 1.5 Hot + ++ + + < 1% -
17 Female 35 1.6 Mixed + ++ + + < 1% -
18 Female 14 6.9 Hot - ++ + +/- 3% ≤ -
19 Female 19 3.5 Mixed - ++ + + 1–2% -
20 Female 47 4.2 Hot + ++ + + < 1% -
21 Male 30 3.8 Hot + ++ + + < 1% -
22 Female 48 1.5 Defective + ++ + + < 1% -
23 Female 41 2.5 Defective + N/A + N/A < 1% +
24 Female 38 6.5 Hot + N/A + N/A < 1% +
25 Female 46 2 Defective + ++ + + 1–2% -
26 Female 28 8 Defective + + + +/- 3% ≤ -
27 Female 16 7 Hot + N/A + N/A < 1% -
28 Female 45 3 - - N/A + +/- < 1% +
29 Female 43 5.2 Defective - N/A + +/- < 1% +
30 Female 22 8.5 Hot + + + + 1–2% -
31 Female 40 8.3 Hot + ++ + + 1–2% -
32 Female 35 1.6 Hot + ++ + + < 1% -
33 Female 38 2 Hot + ++ + N/A 1–2% -
34 Female 40 2.7 Hot + + + N/A < 1% -
35 Female 42 1.5 Hot + ++ + + 1–2% -
36 Female 23 5 Hot + ++ + +/- < 1% -
N/A; not available due to necrosis, immunohistochemistry score (-; negative, +/-; weak, +; moderate, ++; strong)
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and Figure 3), suggesting this metabolic type of SPNs 
might be less progressive and would follow indolent 
clinical course. Considering most patients with SPNs 
are young female patients with active social activity, 
surgery for SPTs with defective type of 18F-FDG uptake 
could be reserved according to patient’s social activity, 
and physical conditions, because it cannot be denied that 
pancreatectomy is related to high rate of postoperative 
morbidity with potential mortality in spite of improved 
perioperative management [29] (Figure 4).
Based on the current observations, further 
investigation of the metabolic differences between 
indolent type SPNs and those with clinically aggressive 
behavior could prove valuable. What makes indolent SPNs 
change to take on an aggressive biologic behavior? What 
differences exist between types of SPN from the view 
point of metabolism? Why should SPNs show increased 
glucose metabolism in spite of low proliferation? Is there 
any specific metabolomics pathway for SPNs? Future 
basic and clinical research should provide answers to this 
surgical enigma.
MATERIALS AND METHODS
Patient selection and clinical data
 The medical records of 36 patients with SPN who 
underwent preoperative 18F-FDG PET/PET-CT scans and 
a pancreatectomy were retrospectively reviewed. The 
clinicopathologic characteristics of the patients, including 
age, gender, radiologic tumor size, and microscopic 
malignant features, were investigated. SPN tissue samples 
from 36 patients were obtained by surgical resection. 
Among them, five fresh tissues that consisted of more 
than 70% tumor cells without previous adjuvant chemo- or 
radiotherapy were selected for analysis of gene expression 
profiles. The specimens were obtained from the archives 
of the Department of Pathology, Yonsei University, Seoul, 
Korea and from the Liver Cancer Specimen Bank of the 
National Research Resource Bank Program of the Korea 
Science and Engineering Foundation under the Ministry 
of Science and Technology. Authorization for the use of 
these tissues for research purposes was obtained from 
the Institutional Review Board of Yonsei University of 
College of Medicine.
18F-FDP PET/ PET-CT protocol
All 18F-FDG PET/PET-CT scans were performed 
with a dedicated PET/CT scanner (Discovery STe, 
GE Healthcare; or Biograph TruePoint 40, Siemens 
Healthcare). All patients fasted for at least 6 h prior to 
the PET/CT scan. A dose of approximately 5.5 MBq/
kg of 18F-FDG was intravenously injected 60 min before 
imaging. First, CT scans were performed at 30 mA and 130 
kVp with the Discovery STe scanner or at 36 mA and 120 
kVp with the Biograph TruePoint scanner without contrast-
enhancement. After the CT scan was complete, a PET 
scan was performed from the neck to the proximal thigh, 
with an acquisition time of 3 min per bed position in a 3D 
mode. PET images were reconstructed using ordered subset 
expectation maximization with attenuation correction. 
Image evaluation and PET-based parameters
 18F-FDG PET/CT images were reviewed by two 
nuclear medicine physicians (Yun M, and Cho A) using 
Table 2: Correlation between intratumoral necrosis and Ki-67 index
Necrosis
P-value
Negative Positive
Ki-67 (%) 0 0 2
0.017
< 1 14 7
1–2 9 1
3 ≤ 3 0
Table 3: Correlation between PET-based parameters and microscopic malignant features of SPNs
Microscopic malignant features
P-value
Absent (N = 29) Present (N = 7)
SUVmax 5.1 ± 4.0 6.9 ± 4.5 0.299
MTV2.5 23.3 ± 47.2 65.3 ± 92.8 0.284
Tumor size 4.9 ± 3.2 5.1 ± 2.9 0.828
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an Advantage Workstation 4.4 (GE Medical Systems). 
Maximum standardized uptake value (SUVmax) and 
metabolic tumor volume (TMV2.5) on PET images were 
measured using the volume viewer software. Each 
tumor was examined with a spherical-shaped volume 
of interest (VOI) that included the entire lesion in the 
axial, sagittal, and coronal planes. By using CT images, 
18F-FDG uptake by normal organs, such as the bowel, 
stomach, and liver, was excluded from the VOI. The 
SUVmax of the VOI was calculated as (decay-corrected 
activity/tissue volume)/(injected dose/body weight). 
MTV2.5 was defined as the total tumor volume with an 
SUV ≥ 2.5. In patients with a SUVmax of < 2.5, MTV2.5 
was not measured. In addition, clinical patterns of 
18F-FDG uptake in SPNs were categorized according to 
the proportion of 18F-FDG uptake over the whole tumor 
volume (hot: ≥ 70%, mixed: 30% ≤ 70%, and defective: 
< 30%, Figure 1). 
mRNA gene expression data preparation and 
statistical analysis
Raw data were extracted using the software 
provided by Illumina Genome Studio v2011.1 (Gene 
Expression Module v1.9.0). Expression intensities were 
normalized using quantile normalization techniques. 
Using the normalized intensities, differentially 
expressed genes (DEGs) between non-neoplastic 
pancreatic tissue and pancreatic tumors (SPN, or PCA) 
were determined using a previously reported integrated 
statistical method [13]. We selected the expression of 
genes involved in glucose metabolism in five SPNs, and 
compared their results to those of normal pancreas and 
PCA specimens. 
Western blot
 Whole lysates from tissue specimens were 
prepared using passive lysis buffer (Promega). Protein 
samples were separated by SDS-PAGE and transferred to 
nitrocellulose membranes. Blots were blocked with Tris-
buffered saline and Tween 20 containing 5% skim milk, 
and incubated overnight at 4°C with primary antibodies 
against GLUT1 (Alpha Diagnostic), HK1, PKM2, LDHA, 
PDHA (Cell Signaling) and ENO2 (antibodies-online). 
After washing, the membranes were incubated with 
horseradish peroxidase-conjugated secondary antibody 
(Santa Cruz Biotechnology) for 1 h at room temperature, 
washed, and developed with luminol reagent (Santa Cruz 
Biotechnology).
Immunohistochemistry
Healthy, available paraffin-embedded tissue 
blocks for the 36 patients were cut into 4-μm sections. 
Immunohistochemical analysis was performed using a 
Ventana XT automated stainer (Ventana Corporation) 
with antibodies against GLUT1 (Alpha Diagnostic), HK1, 
PKM2, LDHA, PDHA (Cell Signaling), ENO2 (antibodies-
Table 4: Correlation between staining intensity of glucose metabolism-related genes and microscopic 
malignant features of SPNs
Microscopic malignant features
P-value
Absent (N = 29) Present  (N = 7)
GLUT1 - 4 1
1.000
+ 25 6
HK1* + 3 1
1.000
++ 17 5
PKM2* +/- 6 0
0.280
+ 14 6
Necrosis - 20 6
0.645
+ 9 1
Ki-67 0 2 0
0.781
< 1 15 6
1–2 10 -
3 ≤ 2 1
Clinical pattern 18FDG-uptake
Defective
Hot+Mixed 17 7
0.070
12 0
* 10 cases were not included due to poor staining.
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online), and Ki-67 (Dako). Immunohistochemical results 
were scored according to staining intensities as follows: -, 
no staining; +/-, weak staining (faint protein expression); 
+, moderate staining (definite protein staining in ≤ 30% 
of tumor cells); or ++, strong staining (definite protein 
expression in > 30% of tumor cells).
Statistical analysis
 Continuous variables are expressed as mean ± 
standard deviation and categorical variables as frequency 
(%). ANOVA and Student’s t-test were used for comparative 
analysis, while chi-square (Fisher’s exact test, or linear-
to-linear association if necessary) was used for analyzing 
clinical patterns of FDG uptake and immunohistochemical 
grades for detecting glucose metabolism-related gene 
expression. Statistical analyses were performed using SPSS 
software, version 20.0 for Windows (SPSS Inc.). P-values < 
0.05 were considered statistically significant.
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